

3-[FLUORO(2,3,5,6-TETRAFLUOROPHENYL)METHYL]-1-PROPYLAZETIDINE
or a pharmaceutically acceptable salt of any of the foregoing compounds.

10. A compound according to claim 1, which is:

(-)-3-[(2,3-DIFLUOROPHENYL)(FLUORO)METHYL]AZETIDINE,

(-)-3-[(3,5-DIFLUOROPHENYL)(FLUORO)METHYL]AZETIDINE,

(-)-3-[FLUORO(2,3,5-TRIFLUOROPHENYL)METHYL]AZETIDINE,

or a pharmaceutically acceptable salt of any of the foregoing compounds.

11. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I is a (-)-enantiomer.

12. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein said compound or salt contains at least one deuterium atom.

13. A pharmaceutical composition, comprising a therapeutically effective amount of a compound according to any one of claims 1-12, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient and/or diluent.

14. A compound according to any one of claims 1-12 or a pharmaceutically acceptable salt thereof, for use as a medicament.

15. Use of a compound according to any one of claims 1-12 for the manufacture of a medicament for the treatment and/or prevention of a disease, disorder and/or condition which is responsive to modulation of monoamines in the cerebral cortex, wherein said disease, disorder and/or condition is selected from the group consisting of dementia, age-related cognitive impairment, cognitive impairment associated with neurodegenerative disorders and/or diseases, autism spectrum disorders, affective disorders, schizophrenia, anxiety disorders, attention deficit hyperactivity disorder (ADHD) and movement disorders.

16. Use according to claim 15, wherein said disease, disorder and/or condition is selected from the group consisting of dementia, age-related cognitive impairment and schizophrenia.